The US contrast agents and radiopharmaceutical market will see\u00a0moderate growth over the forecast period. Market growth will be driven by\u00a0rising\u00a0PET\u00a0and\u00a0MRI\u00a0procedure volumes, and the expanding use of imaging agents in\u00a0CEUS\u00a0and\u00a0PET\u00a0procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities. Additionally, the shift toward value-based care will act as a barrier for certain procedures, favoring those that offer the highest levels of accuracy and clarity in visualization instead. Moving forward, market growth will be driven by the introduction of new contrast agents currently in development or undergoing clinical trials, along with\u00a0FDA\u00a0approvals for expanded indications of existing contrast agents.<\/p>\n
This Medtech 360 Report provides comprehensive data and analysis on the state of the market for contrast agents and radiopharmaceuticals in the US from 2019 through 2033.<\/p>\n","protected":false},"template":"","class_list":["post-585348","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-contrast-agents-and-radiopharmaceuticals","medtech-therapy-area-imaging","medtech-date-983"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/585348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=585348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}